Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Iovance Biotherapeutics (IOVA) over the last 14 years, with Q3 2025 value amounting to $31.2 million.

  • Iovance Biotherapeutics' Accounts Payables changed N/A to $31.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.2 million, marking a year-over-year change of. This contributed to the annual value of $27.5 million for FY2024, which is 1694.89% down from last year.
  • Iovance Biotherapeutics' Accounts Payables amounted to $31.2 million in Q3 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Accounts Payables peaked at $33.1 million during Q4 2023, and registered a low of $19.3 million during Q3 2023.
  • For the 3-year period, Iovance Biotherapeutics' Accounts Payables averaged around $28.9 million, with its median value being $31.2 million (2023).
  • As far as peak fluctuations go, Iovance Biotherapeutics' Accounts Payables tumbled by 1859.88% in 2024, and later soared by 1085.21% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Accounts Payables (Quarter) stood at $33.1 million in 2023, then fell by 16.95% to $27.5 million in 2024, then rose by 13.55% to $31.2 million in 2025.
  • Its last three reported values are $31.2 million in Q3 2025, $32.0 million for Q2 2025, and $28.5 million during Q1 2025.